News Releases

Date	Title
03/07/23	Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
02/28/23	Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
02/21/23	Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
01/31/23	Optinose Announces CEO Transition and Business Update

Jonathan Neely
VP Investor Relations and Business Operations
Email: investors@optinose.com

Keyword Search